nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Melphalan—Chlorambucil—testicular cancer	0.815	1	CrCrCtD
L-DOPA—PSIP1—embryo—testicular cancer	0.0052	0.105	CbGeAlD
L-DOPA—PSIP1—seminal vesicle—testicular cancer	0.00489	0.0983	CbGeAlD
L-DOPA—PSIP1—gonad—testicular cancer	0.00353	0.0711	CbGeAlD
L-DOPA—DDC—embryo—testicular cancer	0.00297	0.0597	CbGeAlD
L-DOPA—PSIP1—female gonad—testicular cancer	0.00287	0.0578	CbGeAlD
L-DOPA—PSIP1—testis—testicular cancer	0.00255	0.0512	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—testicular cancer	0.0025	0.5	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—testicular cancer	0.0025	0.5	CbGdCrCtD
L-DOPA—SLC7A5—seminal vesicle—testicular cancer	0.0025	0.0502	CbGeAlD
L-DOPA—SLC7A8—gonad—testicular cancer	0.00233	0.0468	CbGeAlD
L-DOPA—DRD4—testis—testicular cancer	0.00212	0.0426	CbGeAlD
L-DOPA—SLC7A8—female gonad—testicular cancer	0.00189	0.0381	CbGeAlD
L-DOPA—PSIP1—lymph node—testicular cancer	0.00184	0.0371	CbGeAlD
L-DOPA—SLC7A5—gonad—testicular cancer	0.0018	0.0363	CbGeAlD
L-DOPA—SLC7A8—testis—testicular cancer	0.00168	0.0338	CbGeAlD
L-DOPA—DRD5—female gonad—testicular cancer	0.00157	0.0317	CbGeAlD
L-DOPA—SLC7A5—female gonad—testicular cancer	0.00147	0.0295	CbGeAlD
L-DOPA—DDC—testis—testicular cancer	0.00145	0.0292	CbGeAlD
L-DOPA—SLC16A10—gonad—testicular cancer	0.00138	0.0278	CbGeAlD
L-DOPA—SLC7A5—testis—testicular cancer	0.0013	0.0262	CbGeAlD
L-DOPA—SLC7A8—lymph node—testicular cancer	0.00122	0.0245	CbGeAlD
L-DOPA—DDC—lymph node—testicular cancer	0.00105	0.0212	CbGeAlD
L-DOPA—SLC16A10—testis—testicular cancer	0.000995	0.02	CbGeAlD
L-DOPA—SLC7A5—lymph node—testicular cancer	0.000942	0.019	CbGeAlD
L-DOPA—SLC16A10—lymph node—testicular cancer	0.000722	0.0145	CbGeAlD
L-DOPA—DRD2—testis—testicular cancer	0.00063	0.0127	CbGeAlD
L-DOPA—CYP2D6—female gonad—testicular cancer	0.000427	0.00859	CbGeAlD
L-DOPA—CYP2D6—testis—testicular cancer	0.000379	0.00762	CbGeAlD
L-DOPA—Paraesthesia—Cisplatin—testicular cancer	0.000174	0.00134	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—testicular cancer	0.000174	0.00134	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000174	0.00134	CcSEcCtD
L-DOPA—Dyspnoea—Cisplatin—testicular cancer	0.000173	0.00133	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—testicular cancer	0.000172	0.00132	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000172	0.00132	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—testicular cancer	0.000171	0.00131	CcSEcCtD
L-DOPA—Anorexia—Etoposide—testicular cancer	0.00017	0.0013	CcSEcCtD
L-DOPA—Decreased appetite—Cisplatin—testicular cancer	0.000169	0.0013	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—testicular cancer	0.000168	0.00129	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—testicular cancer	0.000168	0.00129	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000168	0.00129	CcSEcCtD
L-DOPA—Vomiting—Bleomycin—testicular cancer	0.000168	0.00129	CcSEcCtD
L-DOPA—Depression—Methotrexate—testicular cancer	0.000167	0.00128	CcSEcCtD
L-DOPA—Hypotension—Etoposide—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Rash—Bleomycin—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Pain—Cisplatin—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Dermatitis—Bleomycin—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Hypersensitivity—Ifosfamide—testicular cancer	0.000166	0.00128	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000163	0.00125	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—testicular cancer	0.000162	0.00125	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—testicular cancer	0.000162	0.00125	CcSEcCtD
L-DOPA—Asthenia—Ifosfamide—testicular cancer	0.000162	0.00124	CcSEcCtD
L-DOPA—Feeling abnormal—Cisplatin—testicular cancer	0.00016	0.00123	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—testicular cancer	0.00016	0.00123	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—testicular cancer	0.00016	0.00123	CcSEcCtD
L-DOPA—Pruritus—Ifosfamide—testicular cancer	0.000159	0.00123	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—testicular cancer	0.000159	0.00122	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—testicular cancer	0.000159	0.00122	CcSEcCtD
L-DOPA—Somnolence—Etoposide—testicular cancer	0.000158	0.00122	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—testicular cancer	0.000158	0.00122	CcSEcCtD
L-DOPA—Nausea—Bleomycin—testicular cancer	0.000157	0.0012	CcSEcCtD
L-DOPA—Vomiting—Dactinomycin—testicular cancer	0.000156	0.0012	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—testicular cancer	0.000156	0.0012	CcSEcCtD
L-DOPA—Rash—Dactinomycin—testicular cancer	0.000155	0.00119	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—testicular cancer	0.000155	0.00119	CcSEcCtD
L-DOPA—Diarrhoea—Ifosfamide—testicular cancer	0.000154	0.00119	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—testicular cancer	0.000154	0.00118	CcSEcCtD
L-DOPA—Fatigue—Etoposide—testicular cancer	0.000153	0.00118	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—testicular cancer	0.000153	0.00118	CcSEcCtD
L-DOPA—Pain—Etoposide—testicular cancer	0.000152	0.00117	CcSEcCtD
L-DOPA—Constipation—Etoposide—testicular cancer	0.000152	0.00117	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—testicular cancer	0.000152	0.00117	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000151	0.00116	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—testicular cancer	0.000151	0.00116	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—testicular cancer	0.00015	0.00115	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—testicular cancer	0.00015	0.00115	CcSEcCtD
L-DOPA—Dizziness—Ifosfamide—testicular cancer	0.000149	0.00115	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—testicular cancer	0.000148	0.00114	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—testicular cancer	0.000148	0.00114	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—testicular cancer	0.000147	0.00113	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—testicular cancer	0.000147	0.00113	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—testicular cancer	0.000147	0.00113	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—testicular cancer	0.000146	0.00112	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—testicular cancer	0.000146	0.00112	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—testicular cancer	0.000146	0.00112	CcSEcCtD
L-DOPA—Vomiting—Ifosfamide—testicular cancer	0.000143	0.0011	CcSEcCtD
L-DOPA—Hypersensitivity—Cisplatin—testicular cancer	0.000143	0.0011	CcSEcCtD
L-DOPA—Rash—Ifosfamide—testicular cancer	0.000142	0.00109	CcSEcCtD
L-DOPA—Dermatitis—Ifosfamide—testicular cancer	0.000142	0.00109	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000142	0.00109	CcSEcCtD
L-DOPA—Urticaria—Etoposide—testicular cancer	0.000141	0.00109	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—testicular cancer	0.000141	0.00108	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—testicular cancer	0.000141	0.00108	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—testicular cancer	0.000141	0.00108	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—testicular cancer	0.000141	0.00108	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—testicular cancer	0.00014	0.00108	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—testicular cancer	0.00014	0.00107	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—testicular cancer	0.000139	0.00107	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—testicular cancer	0.000139	0.00107	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—testicular cancer	0.000138	0.00106	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—testicular cancer	0.000135	0.00104	CcSEcCtD
L-DOPA—Nausea—Ifosfamide—testicular cancer	0.000134	0.00103	CcSEcCtD
L-DOPA—Diarrhoea—Cisplatin—testicular cancer	0.000133	0.00102	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—testicular cancer	0.000133	0.00102	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—testicular cancer	0.000131	0.00101	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—testicular cancer	0.000131	0.00101	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—testicular cancer	0.000131	0.001	CcSEcCtD
L-DOPA—Flushing—Epirubicin—testicular cancer	0.00013	0.001	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—testicular cancer	0.00013	0.001	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—testicular cancer	0.00013	0.000999	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—testicular cancer	0.000129	0.000994	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—testicular cancer	0.000128	0.000986	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—testicular cancer	0.000128	0.000983	CcSEcCtD
L-DOPA—Asthenia—Etoposide—testicular cancer	0.000128	0.000981	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—testicular cancer	0.000127	0.000979	CcSEcCtD
L-DOPA—Back pain—Methotrexate—testicular cancer	0.000126	0.000971	CcSEcCtD
L-DOPA—Pruritus—Etoposide—testicular cancer	0.000126	0.000968	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—testicular cancer	0.000125	0.000964	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—testicular cancer	0.000124	0.000954	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—testicular cancer	0.000123	0.000949	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—testicular cancer	0.000123	0.000946	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—testicular cancer	0.000123	0.000946	CcSEcCtD
L-DOPA—Rash—Cisplatin—testicular cancer	0.000122	0.000941	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—testicular cancer	0.000122	0.000941	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—testicular cancer	0.000122	0.000936	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—testicular cancer	0.000121	0.000932	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—testicular cancer	0.000121	0.000928	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—testicular cancer	0.000121	0.000927	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—testicular cancer	0.00012	0.000926	CcSEcCtD
L-DOPA—Tension—Epirubicin—testicular cancer	0.00012	0.000922	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—testicular cancer	0.00012	0.00092	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—testicular cancer	0.000119	0.000913	CcSEcCtD
L-DOPA—Back pain—Epirubicin—testicular cancer	0.000118	0.000909	CcSEcCtD
L-DOPA—Malaise—Methotrexate—testicular cancer	0.000118	0.000905	CcSEcCtD
L-DOPA—Dizziness—Etoposide—testicular cancer	0.000118	0.000905	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—testicular cancer	0.000117	0.000903	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—testicular cancer	0.000117	0.000899	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—testicular cancer	0.000116	0.000892	CcSEcCtD
L-DOPA—Nausea—Cisplatin—testicular cancer	0.000115	0.000887	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—testicular cancer	0.000115	0.000885	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—testicular cancer	0.000115	0.000882	CcSEcCtD
L-DOPA—Cough—Methotrexate—testicular cancer	0.000114	0.000876	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—testicular cancer	0.000114	0.000875	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—testicular cancer	0.000113	0.000872	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—testicular cancer	0.000113	0.00087	CcSEcCtD
L-DOPA—Vomiting—Etoposide—testicular cancer	0.000113	0.00087	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—testicular cancer	0.000113	0.000868	CcSEcCtD
L-DOPA—Agitation—Epirubicin—testicular cancer	0.000112	0.000863	CcSEcCtD
L-DOPA—Rash—Etoposide—testicular cancer	0.000112	0.000863	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—testicular cancer	0.000112	0.000862	CcSEcCtD
L-DOPA—Headache—Etoposide—testicular cancer	0.000111	0.000857	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—testicular cancer	0.000111	0.000857	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—testicular cancer	0.000111	0.000855	CcSEcCtD
L-DOPA—Tension—Doxorubicin—testicular cancer	0.000111	0.000853	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—testicular cancer	0.000111	0.000851	CcSEcCtD
L-DOPA—Malaise—Epirubicin—testicular cancer	0.00011	0.000847	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—testicular cancer	0.00011	0.000844	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—testicular cancer	0.00011	0.000844	CcSEcCtD
L-DOPA—Syncope—Epirubicin—testicular cancer	0.00011	0.000843	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—testicular cancer	0.000109	0.000841	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—testicular cancer	0.000109	0.000841	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—testicular cancer	0.000109	0.000836	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—testicular cancer	0.000108	0.00083	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—testicular cancer	0.000107	0.000826	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—testicular cancer	0.000107	0.000826	CcSEcCtD
L-DOPA—Cough—Epirubicin—testicular cancer	0.000107	0.00082	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—testicular cancer	0.000107	0.000819	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—testicular cancer	0.000106	0.000814	CcSEcCtD
L-DOPA—Nausea—Etoposide—testicular cancer	0.000106	0.000813	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—testicular cancer	0.000106	0.000811	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—testicular cancer	0.000105	0.000807	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—testicular cancer	0.000105	0.000804	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—testicular cancer	0.000104	0.000802	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—testicular cancer	0.000104	0.0008	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—testicular cancer	0.000104	0.000799	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—testicular cancer	0.000104	0.000797	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—testicular cancer	0.000103	0.000792	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—testicular cancer	0.000103	0.00079	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—testicular cancer	0.000102	0.000784	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—testicular cancer	0.000102	0.000782	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—testicular cancer	0.000102	0.000781	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—testicular cancer	0.000101	0.00078	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—testicular cancer	0.000101	0.000778	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—testicular cancer	0.000101	0.000773	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—testicular cancer	9.99e-05	0.000768	CcSEcCtD
L-DOPA—Oedema—Epirubicin—testicular cancer	9.97e-05	0.000767	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—testicular cancer	9.96e-05	0.000766	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—testicular cancer	9.94e-05	0.000764	CcSEcCtD
L-DOPA—Cough—Doxorubicin—testicular cancer	9.87e-05	0.000759	CcSEcCtD
L-DOPA—Shock—Epirubicin—testicular cancer	9.81e-05	0.000754	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—testicular cancer	9.8e-05	0.000753	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—testicular cancer	9.77e-05	0.000751	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—testicular cancer	9.76e-05	0.000751	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—testicular cancer	9.64e-05	0.000741	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—testicular cancer	9.64e-05	0.000741	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—testicular cancer	9.63e-05	0.00074	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—testicular cancer	9.59e-05	0.000738	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—testicular cancer	9.57e-05	0.000736	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—testicular cancer	9.51e-05	0.000731	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—testicular cancer	9.51e-05	0.000731	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—testicular cancer	9.5e-05	0.000731	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—testicular cancer	9.48e-05	0.000728	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—testicular cancer	9.42e-05	0.000724	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—testicular cancer	9.38e-05	0.000721	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—testicular cancer	9.32e-05	0.000717	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—testicular cancer	9.31e-05	0.000715	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—testicular cancer	9.27e-05	0.000712	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—testicular cancer	9.23e-05	0.00071	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—testicular cancer	9.2e-05	0.000707	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—testicular cancer	9.19e-05	0.000706	CcSEcCtD
L-DOPA—Pain—Methotrexate—testicular cancer	9.11e-05	0.000701	CcSEcCtD
L-DOPA—Shock—Doxorubicin—testicular cancer	9.08e-05	0.000698	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—testicular cancer	9.04e-05	0.000695	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—testicular cancer	9.02e-05	0.000694	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—testicular cancer	8.96e-05	0.000689	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—testicular cancer	8.92e-05	0.000686	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—testicular cancer	8.89e-05	0.000684	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—testicular cancer	8.87e-05	0.000682	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—testicular cancer	8.8e-05	0.000676	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—testicular cancer	8.78e-05	0.000675	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—testicular cancer	8.78e-05	0.000675	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—testicular cancer	8.72e-05	0.00067	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—testicular cancer	8.67e-05	0.000667	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—testicular cancer	8.62e-05	0.000663	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—testicular cancer	8.61e-05	0.000662	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—testicular cancer	8.6e-05	0.000661	CcSEcCtD
L-DOPA—Constipation—Epirubicin—testicular cancer	8.53e-05	0.000656	CcSEcCtD
L-DOPA—Pain—Epirubicin—testicular cancer	8.53e-05	0.000656	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—testicular cancer	8.47e-05	0.000651	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—testicular cancer	8.43e-05	0.000648	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—testicular cancer	8.35e-05	0.000642	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—testicular cancer	8.29e-05	0.000637	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—testicular cancer	8.23e-05	0.000633	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—testicular cancer	8.22e-05	0.000632	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—testicular cancer	8.2e-05	0.000631	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—testicular cancer	8.16e-05	0.000627	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—testicular cancer	8.12e-05	0.000625	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—testicular cancer	8.02e-05	0.000617	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.97e-05	0.000613	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—testicular cancer	7.96e-05	0.000612	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—testicular cancer	7.92e-05	0.000609	CcSEcCtD
L-DOPA—Pain—Doxorubicin—testicular cancer	7.89e-05	0.000607	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—testicular cancer	7.89e-05	0.000607	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—testicular cancer	7.88e-05	0.000606	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—testicular cancer	7.85e-05	0.000604	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—testicular cancer	7.65e-05	0.000588	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—testicular cancer	7.61e-05	0.000585	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—testicular cancer	7.55e-05	0.00058	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—testicular cancer	7.54e-05	0.00058	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—testicular cancer	7.35e-05	0.000565	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—testicular cancer	7.33e-05	0.000564	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—testicular cancer	7.3e-05	0.000561	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—testicular cancer	7.29e-05	0.000561	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—testicular cancer	7.16e-05	0.00055	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—testicular cancer	7.06e-05	0.000543	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—testicular cancer	7.05e-05	0.000542	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—testicular cancer	6.82e-05	0.000525	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—testicular cancer	6.8e-05	0.000523	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—testicular cancer	6.78e-05	0.000521	CcSEcCtD
L-DOPA—Rash—Methotrexate—testicular cancer	6.72e-05	0.000517	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—testicular cancer	6.71e-05	0.000516	CcSEcCtD
L-DOPA—Headache—Methotrexate—testicular cancer	6.68e-05	0.000513	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—testicular cancer	6.62e-05	0.000509	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—testicular cancer	6.6e-05	0.000507	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—testicular cancer	6.53e-05	0.000502	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—testicular cancer	6.34e-05	0.000488	CcSEcCtD
L-DOPA—Nausea—Methotrexate—testicular cancer	6.33e-05	0.000487	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—testicular cancer	6.31e-05	0.000485	CcSEcCtD
L-DOPA—Rash—Epirubicin—testicular cancer	6.29e-05	0.000483	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—testicular cancer	6.28e-05	0.000483	CcSEcCtD
L-DOPA—Headache—Epirubicin—testicular cancer	6.25e-05	0.00048	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—testicular cancer	6.1e-05	0.000469	CcSEcCtD
L-DOPA—Nausea—Epirubicin—testicular cancer	5.92e-05	0.000455	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—testicular cancer	5.87e-05	0.000451	CcSEcCtD
L-DOPA—Rash—Doxorubicin—testicular cancer	5.82e-05	0.000447	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—testicular cancer	5.81e-05	0.000447	CcSEcCtD
L-DOPA—Headache—Doxorubicin—testicular cancer	5.78e-05	0.000444	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—testicular cancer	5.48e-05	0.000421	CcSEcCtD
